Regeneron Pharmaceuticals has become the 17th major drugmaker to reach a pricing agreement with the Trump administration. Under the “Most Favored Nation” (MFN) framework, Regeneron secures immunity from 100% tariffs on branded drug imports in exchange for significant price concessions. Specifically, the company will slash the price of its cholesterol medication, Praluent, by 58% to $225 for purchases made through the government’s TrumpRx.gov platform, and has pledged MFN pricing for all forthcoming medicines.
In a landmark move for rare disease treatment, Regeneron will provide its newly approved gene therapy, Otarmeni, at no cost to eligible American patients. Otarmeni, which targets a specific genetic form of deafness linked to OTOF gene mutations, received regulatory clearance on April 23 following Phase I/II clinical trials where 80% of participants showed hearing improvements. This initiative aims to bridge the treatment gap for the small number of newborns affected by this condition annually.
Furthermore, Regeneron has committed to investing $27 billion in domestic R&D and manufacturing capacity through 2029. This strategic investment is projected to more than double the company’s U.S.-based production footprint, aligning with the administration’s “America First” agenda to revitalize domestic pharmaceutical manufacturing and lower healthcare costs to levels comparable with other developed nations.